Key bottlenecks in M/XDR-TB control and patient care
Restricting the availability of anti-TB medicines
The unregulated availability of anti-TB medicines, whether first-line or second-line, is fuelling the development of MDR and XDR-TB. This paper calls upon governments to ban immediately “over-the-counter” sales of such products. It further advises the accreditation of practitioners in the public and private sectors to prescribe anti-TB medicines and restrictions in the right to carry out prescribing practices to accredited practitioners.